Skip to main content

Table 2 Observed weekly transition relative frequencies (%) between the eight health states from the first four weeks of the RGH-188-005 clinical trial

From: Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine

From [row] / to [col] 1 2 3 4 5 6 7 8 n
Risperidone
 1 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2
 2 3.31 80.99 0.00 9.09 5.79 0.83 0.00 0.00 121
 3 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 2
 4 0.00 22.10 0.55 74.31 0.83 2.21 0.00 0.00 362
 5 0.00 16.07 0.00 3.57 75.00 5.36 0.00 0.00 56
 6 0.00 2.87 0.00 8.91 12.07 76.15 0.00 0.00 348
 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0
 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0
Cariprazine
 1 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3
 2 6.03 87.07 0.00 5.17 1.72 0.00 0.00 0.00 116
 3 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 1
 4 0.00 19.89 0.27 75.33 0.53 3.98 0.00 0.00 377
 5 0.00 22.92 0.00 0.00 70.83 6.25 0.00 0.00 48
 6 0.00 3.51 0.00 11.99 10.53 73.98 0.00 0.00 342
 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0
 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0
  1. n number of observations
  2. Source: Appendix of Németh et al. 2017 [9]
\